AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39330494
Drug: Improvement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvement of glycemic control through medical intervention (insulin introduction, changes in multi-injection therapy, pump therapy introduction, therapeutic education)
Trial: 39330966
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of PCV13
Trial: 39330966
Drug: 40% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% dose of PCV13
Trial: 39330966
Drug: 20% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% dose of PCV13
Trial: 39330966
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of PCV10
Trial: 39330966
Drug: 40% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% dose of PCV10
Trial: 39330966
Drug: 20% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% dose of PCV10
Trial: 39330966
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of PCV10 (three primary doses without a booster)
Trial: 39330966
Drug: Vaccine-serotype carriage
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-serotype carriage
Trial: 39331131
Drug: Anatomic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anatomic treatment
Trial: 39331218
Drug: topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical therapy or methotrexate
Trial: 39331638
Drug: Filgotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib 200 mg and 100 mg
Trial: 39331724
Drug: Daratumumab and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab and lenalidomide (D-R) maintenance therapy
Trial: 39331837
Drug: Everolimus (EVR)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (EVR) therapy
Trial: 39331837
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EVR with decreased doses of calcineurin inhibitors (tacrolimus, cyclosporine)
Trial: 39332395
Drug: Finerenone (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone (titrated to either 20 mg or 40 mg)
Trial: 39332418
Drug: mRNA-1273.222 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273.222 (50 μg dose)
Trial: 39332900
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) recanalization
Trial: 39333450
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment after primary surgery
Trial: 39333909
Drug: Anti-Spike IgG
RxNorm normalized name: spike lavender oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Spike IgG antibody levels in the control group
Trial: 39333909
Drug: Anti-Spike IgG
RxNorm normalized name: spike lavender oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Spike IgG antibody levels in specific populations
Trial: 39333909
Drug: Anti-RBD IgG
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-RBD IgG antibody levels in specific populations
Trial: 39333909
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies in specific populations
Trial: 39333988
Drug: Anlotinib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib at 12 mg once daily (QD) and S-1 at 60 mg twice daily (BID) for 2 weeks, followed by a 1-week treatment-free interval, then maintenance therapy with S-1 monotherapy at 60 mg BID for 2 weeks, followed by a 1-week treatment-free interval until disease progression.
Trial: 39334042
Drug: Improvisational music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvisational music therapy for 12 weeks
Trial: 39334053
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment (98.7% of patients) including risperidone (83.6%) with a mean dose of 8.0 ± 5.9 mg/day
Trial: 39334053
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antipsychotics with benzodiazepines (34.5%)
Trial: 39334053
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antipsychotics with antidepressants (14.4%)
Trial: 39334053
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antipsychotics with antidepressants and benzodiazepines (25.9%)
Trial: 39334053
Drug: Antipsychotic monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic monotherapy (17.9%)
Trial: 39334120
Drug: Problem-solving-based psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving-based psychological intervention administered face-to-face (PSPI-P)
Trial: 39334129
Drug: Bivalirudin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin plus a post-PCI high-dose infusion for 2-4 hours
Trial: 39334129
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with bail-out GPI
Trial: 39334205
Drug: Immunosuppressive or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive or cytotoxic therapy
Trial: 39334218
Drug: Daily bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily bilateral hamstring stretching exercises for six weeks
Trial: 39334224
Drug: Goal-directed tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goal-directed tranexamic acid administration (Group-GDT)
Trial: 39334224
Drug: Preemptive tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preemptive tranexamic acid administration (Group-P)
Trial: 39334260
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (AZI) 20 mg/kg bodyweight administered at 6 weeks, 9 months, and 15 months of age
Trial: 39334260
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (AZI)
Trial: 39337333
Drug: Tumor-infiltrating lymphocyte
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor-infiltrating lymphocyte (TIL) therapy (lifileucel)
Trial: 39337423
Drug: Nutraceutical supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical supplementation (olive (poly)phenol, vitamin C, and vitamin B preparation)
Trial: 39339791
Drug: Daily orange
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily orange consumption, dosage not specified, duration not specified
Trial: 39340109
Drug: B.1.351 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B.1.351 vaccine
Trial: 39340688
Drug: Colistin (CMS)
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colistin (CMS) administered at a dosage of 6.75 MUI q12 after a 9 MIU loading dose.
Trial: 39340691
Drug: Celecoxib plus
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib plus standard PD treatment (levodopa/carbidopa)
Trial: 39340691
Drug: Standard PD
RxNorm normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PD treatment (levodopa/carbidopa)
Trial: 39340711
Drug: Finerenone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone (10 mg and 20 mg)
Trial: 39340758
Drug: Lamotrigine 200
RxNorm normalized name: lamotrigine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 200 mg orally for 26 weeks
Trial: 39341405
Drug: N protein-based
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N protein-based vaccine (50 µg)
Trial: 39341482
Drug: Penn Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penn Medicine Healthy Heart intervention
Trial: 39342463
Drug: SCH 727965
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 727965 (dinaciclib) 50 mg/m
Trial: 39343051
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with 3 balloon dilations 3 weeks apart and/or needle-knife stricturotomy (NKSt)
Trial: 39343051
Drug: Concurrent intensified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent intensified drug treatment
Trial: 39343244
Drug: Oral nirmatrelvir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nirmatrelvir/ritonavir (NMV/r) 300/100 mg BID
Trial: 39343244
Drug: Intravenous sotrovimab
RxNorm normalized name: sotrovimab
DrugBank: Sotrovimab (DB16355)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intravenous sotrovimab (SOT)
Trial: 39343244
Drug: Intramuscular tixagevimab/cilgavimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular tixagevimab/cilgavimab (TGM/CGM)
Trial: 39343247
Drug: NVX-CoV2373 (2-Dose)
RxNorm normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX-CoV2373 (2-Dose) administered on day 0 and day 21
Trial: 39343309
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of psilocybin
Trial: 39343313
Drug: Internet-based interpersonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based interpersonal psychotherapy (IPT) for 10 weeks with weekly therapist guidance
Trial: 39343425
Drug: High-dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks
Trial: 39343510
Drug: Ipilimumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (1 mg/kg intravenously every 6 weeks) plus Nivolumab (240 mg intravenously every 2 weeks)
Trial: 39343865
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral pre-exposure prophylaxis pills
Trial: 39343865
Drug: Monthly dapivirine
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly dapivirine vaginal ring
Trial: 39343942
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (weekly, supervised, 30-45 min sessions, encouraged to accumulate more than 5000 steps per day)
Trial: 39344281
Drug: Ganaplacide 200
RxNorm normalized name: Ganaplacide
DrugBank: Ganaplacide (DB16173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganaplacide 200 mg plus LUM-SDF 960 mg (run-in part)
Trial: 39344366
Drug: Anticoagulant switching
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant switching
Trial: 39344637
Drug: Colchicine treatment
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine treatment (exact dosage and duration not specified)
Trial: 39344637
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (exact treatment not specified)
Trial: 39345688
Drug: Oviderm® or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oviderm® or Canoderm® (intervention creams)
Trial: 39345688
Drug: Decubal® lipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decubal® lipid cream (comparator)
Trial: 39345833
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral doses of 14,000 IU vitamin D
Trial: 39346010
Drug: Bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation through a mid-gut tube
Trial: 39346010
Drug: Bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation by oral administration
Trial: 39347697
Drug: Mavacamten treatment
RxNorm normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mavacamten treatment for 26 weeks starting at 2.5 mg and potentially titrated up to 5 mg at week 14.
Trial: 39348419
Drug: Conventional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapies for dcSSc
Trial: 39348472
Drug: Trebananib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trebananib (30 mg/kg weekly) plus Pembrolizumab (200 mg every 3 weeks)
Trial: 39348664
Drug: R-CHOP therapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
Trial: 39348664
Drug: R-CHOP therapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP therapy
Trial: 39348677
Drug: Weekly email
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly email newsletter (control)
Trial: 39348705
Drug: <10 g/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <10 g/dL transfusion strategy
Trial: 39348705
Drug: <9 g/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <9 g/dL transfusion strategy
Trial: 39348705
Drug: <8 g/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <8 g/dL transfusion strategy
Trial: 39348705
Drug: <7 g/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <7 g/dL transfusion strategy
Trial: 39349061
Drug: Neoadjuvant ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy (IPI-NIVO-CRT); IPI 1 mg/kg intravenous and NIVO 360 mg intravenous on day-1, followed by chemotherapy plus NIVO 360 mg 3 weeks later; Thoracic radiotherapy was 50 or 60 Gy, in once-daily doses of 2 Gy.
Trial: 39349282
Drug: Optimal secondary
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal secondary prevention therapy at discharge
Trial: 39349554
Drug: E2 cypionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 cypionate (5 mg, IM) and micronized P4 (200 mg, PO)
Trial: 39350021
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose intake during OGTT
Trial: 39350097
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment control group (access to the programme five months after randomization)
Trial: 39350107
Drug: Implants in
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants in lateral incisor positions
Trial: 39350107
Drug: Implants in
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants in canine positions
Trial: 39350954
Drug: Adjunctive minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive minocycline
Trial: 39350954
Drug: Adjunctive celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive celecoxib
Trial: 39351312
Drug: Preoperative exercise
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative exercise intervention (4-week program including aerobic exercise three times a week, muscle strengthening exercise twice a week, and respiratory muscle exercise once a day)
Trial: 39351353
Drug: Unsupervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised exercise (UNSUP) - 16-week, telehealth-based, periodized aerobic and resistance exercise program, performed three days per week, using the same exercise prescription parameters as the SUP group.
Trial: 39351849
Drug: Patients treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients treated without the use of IV therapy
Trial: 39351849
Drug: Patients not
RxNorm normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not on antihypertensive therapy at enrollment
Trial: 39352135
Drug: SPR720, phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPR720, phosphate ester prodrug, oral administration, dosage and duration not specified
Trial: 39352476
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g nori (aiming to provide 2.4 µg vitamin B)
Trial: 39352693
Drug: TEACHH intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TEACHH intervention (health literacy-informed teaching, pictorial materials, color- and shape-coded medication labels, medication demonstration, two Zoom-based follow-up visits)
Trial: 39352751
Drug: High-dose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IV ascorbic acid therapy
Trial: 39352775
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% via intercostal catheter at a flow rate of 6-8 ml/h for 72 hours after surgery
Trial: 39353160
Drug: Serum Epstein-Barr
RxNorm normalized name: Epstein-Barr virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum Epstein-Barr virus (EBV) viral capsid antigen/nuclear antigen 1-immunoglobulin A antibody tests in the screening group
Trial: 39353163
Drug: Roxadustat (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (100, 120, or 150 mg three times a week for 12 weeks)
Trial: 39353584
Drug: Clinical Frailty
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical Frailty Scale administered at baseline, 3 months, and 12 months post-inclusion
Trial: 39353584
Drug: EQ-5D-5L administered
RxNorm normalized name: Anthelcide EQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EQ-5D-5L administered at baseline, 3 months, and 12 months post-inclusion
Trial: 39353631
Drug: SARS-CoV-2 vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccination (first dose)
Trial: 39353631
Drug: SARS-CoV-2 vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccination (second dose)
Trial: 39353677
Drug: DMEK plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMEK plus topical placebo
Trial: 39353677
Drug: DSO plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSO plus topical ripasudil 0.4%
Trial: 39353749
Drug: Leronlimab (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leronlimab (700 mg)
Trial: 39354195
Drug: CD5-gene-edited CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD5-gene-edited CAR-T cell therapy targeting CD5
Trial: 39354558
Drug: Brazilian Cardioprotective
RxNorm normalized name: BRAZILIAN PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazilian Cardioprotective diet supplemented with 30 g/day of mixed nuts (10 g of peanuts; 10 g of cashew; 10 g of Brazil nuts)
Trial: 39354558
Drug: Brazilian Cardioprotective
RxNorm normalized name: BRAZILIAN PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazilian Cardioprotective diet supplemented with 30 g/day of mixed nuts
Trial: 39354619
Drug: Double-dose ESWT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose ESWT (4000 pulses per session)
Trial: 39354619
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (half the dose, 2000 pulses per session)
Trial: 39354625
Drug: JS007 (anti-CTLA-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS007 (anti-CTLA-4 antibody) administered intravenously every 3 weeks at doses of 0.03, 0.3, 1, 3, and 10 mg/kg.
Trial: 39354625
Drug: JS007 (anti-CTLA-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS007 (anti-CTLA-4 antibody) administered intravenously.
Trial: 39355793
Drug: Prolonged 120-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged 120-h meropenem antibiotic prophylaxis (Group B)
Trial: 39355793
Drug: Standard 24-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 24-h antibiotic prophylaxis (Group A)
Trial: 39355924
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor antagonist treatment in patients with PA
Trial: 39356043
Drug: Brivaracetam (BRV)
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Brivaracetam (BRV) treatment, median dose 1.0 mg/kg/day (range 0.4-7.5 mg/kg/day)